Dihydrolipoamide dehydrogenase

DLD
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 3RNM, 1ZMC, 1ZMD, 1ZY8, 2F5Z
Identifiers
Aliases	DLD, DLDD, DLDH, E3, GCSL, LAD, PHE3, dihydrolipoamide dehydrogenase, Dihydrolipoamide dehydrogenase, OGDC-E3
External IDs	OMIM: 238331; MGI: 107450; HomoloGene: 84; GeneCards: DLD; OMA:DLD - orthologs
Gene location (Human) Chr. Chromosome 7 (human) Band 7q31.1 Start 107,891,162 bp End 107,931,730 bp
Gene location (Mouse) Chr. Chromosome 12 (mouse) Band 12 A2|12 13.43 cM Start 31,381,276 bp End 31,401,452 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in right ventricle biceps brachii Skeletal muscle tissue of biceps brachii thoracic diaphragm Skeletal muscle tissue of rectus abdominis vastus lateralis muscle body of tongue mucosa of sigmoid colon jejunal mucosa rectum Top expressed in saccule cardiac muscle tissue of left ventricle otic placode tail of embryo extraocular muscle intercostal muscle soleus muscle extensor digitorum longus muscle interventricular septum plantaris muscle More reference expression data BioGPS n/a
Gene ontology Molecular function flavin adenine dinucleotide binding NAD binding dihydrolipoyl dehydrogenase activity oxidoreductase activity pyruvate dehydrogenase (NAD+) activity lipoamide binding oxidoreductase activity, acting on a sulfur group of donors, NAD(P) as acceptor electron transfer activity protein binding Cellular component oxoglutarate dehydrogenase complex myelin sheath pyruvate dehydrogenase complex cilium acrosomal matrix nucleoplasm mitochondrial matrix mitochondrion acrosomal vesicle cytoplasmic vesicle motile cilium cell projection nucleus Biological process mitochondrial acetyl-CoA biosynthetic process from pyruvate regulation of membrane potential ageing branched-chain amino acid catabolic process tricarboxylic acid cycle 2-oxoglutarate metabolic process lysine catabolic process regulation of acetyl-CoA biosynthetic process from pyruvate cell redox homeostasis proteolysis lipoate metabolic process dihydrolipoamide metabolic process gastrulation pyruvate metabolic process sperm capacitation acetyl-CoA biosynthetic process from pyruvate mitochondrial electron transport, NADH to ubiquinone cellular nitrogen compound metabolic process histone succinylation Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 1738 13382 Ensembl ENSG00000091140 ENSMUSG00000020664 UniProt P09622 O08749 RefSeq (mRNA) NM_001289752 NM_000108 NM_001289750 NM_001289751 NM_007861 RefSeq (protein) NP_000099 NP_001276679 NP_001276680 NP_001276681 NP_031887 Location (UCSC) Chr 7: 107.89 – 107.93 Mb Chr 12: 31.38 – 31.4 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Dihydrolipoamide dehydrogenase (DLD), also known as dihydrolipoyl dehydrogenase, mitochondrial, is an enzyme that in humans is encoded by the DLD gene. DLD is a flavoprotein enzyme that oxidizes dihydrolipoamide to lipoamide.

Dihydrolipoamide dehydrogenase (DLD) is a mitochondrial enzyme that plays a vital role in energy metabolism in eukaryotes. This enzyme is required for the complete reaction of at least five different multi-enzyme complexes. Additionally, DLD is a flavoenzyme oxidoreductase that contains a reactive disulfide bridge and a FAD cofactor that are directly involved in catalysis. The enzyme associates into tightly bound homodimers required for its enzymatic activity.

• 
  Lipoamide
• 
  Dihydrolipoamide

Structure

The protein encoded by the DLD gene comes together with another protein to form a dimer in the central metabolic pathway. Several amino acids within the catalytic pocket have been identified as important to DLD function, including R281 and N473. Although the overall fold of the human enzyme is similar to that of yeast, the human structure is different in that it has two loops that extend from the general protein structure and into the FAD binding sites when bound the NAD+ molecule, required for catalysis, is not close to the FAD moiety. However, when NADH is bound instead, it is stacked directly op top of the FAD central structure. The current hE3 structures show directly that the disease-causing mutations occur at three locations in the human enzyme: the dimer interface, the active site, and the FAD and NAD(+)-binding sites.

Function

The DLD homodimer functions as the E3 component of the pyruvate, α-ketoglutarate, α-adipate and branched-chain amino acid-dehydrogenase complexes and the glycine cleavage system, all in the mitochondrial matrix. In these complexes, DLD converts dihydrolipoic acid and NAD+ into lipoic acid and NADH. DLD also has diaphorase activity, being able to catalyze the oxidation of NADH to NAD+ by using different electron acceptors such as O₂, labile ferric iron, nitric oxide, and ubiquinone. DLD is thought to have a pro-oxidant role by reducing oxygen to a superoxide or ferric to ferrous iron, which then catalyzes production of hydroxyl radicals. Diaphorase activity of DLD may have an antioxidant role through its ability to scavenge nitric oxide and to reduce ubiquinone to ubiquinol. The dihyrolipamide dehydrogenase gene is known to have multiple splice variants.

Moonlighting function

Certain DLD mutations can simultaneously induce the loss of a primary metabolic activity and the gain of a moonlighting proteolytic activity. The moonlighting proteolytic activity of DLD is revealed by conditions that destabilize the DLD homodimer and decrease its DLD activity. Acidification of the mitochondrial matrix, as a result of ischemia-reperfusion injury, can disrupt the quaternary structure of DLD leading to decreased dehydrogenase activity and increased diaphorase activity. The moonlighting proteolytic activity of DLD could also arise under pathological conditions. Proteolytic activity can further complicate the reduction in energy metabolism and an increase in oxidative damage as a result of decreased DLD activity and an increase in diaphorase activity respectively. With its proteolytic function, DLD removes a functionally vital domain from the N-terminus of frataxin, a mitochondrial protein involved in iron metabolism and antioxidant protection.

Clinical significance

In humans, mutations in DLD are linked to a severe disorder of infancy with failure to thrive, hypotonia, and metabolic acidosis. DLD deficiency manifests itself in a great degree of variability, which has been attributed to varying effects of different DLD mutations on the stability of the protein and its ability to dimerize or interact with other components of the three α-ketoacid dehydrogenase complexes. With its proteolytic function, DLD causes a deficiency in frataxin, which leads to the neurodegenerative and cardiac disease, Friedreich's ataxia.

Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. [[File: [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] |alt=TCACycle_WP78 edit]] TCACycle_WP78 edit

Click on genes, proteins and metabolites below to link to respective articles. [[File: [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] [[ ]] |alt=Glycolysis and Gluconeogenesis edit]] Glycolysis and Gluconeogenesis edit

Enzyme regulation

This protein may use the morpheein model of allosteric regulation.

See also

• Lipoic acid

Further reading

• Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, et al. (February 2009). "Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study". Nature Genetics. 41 (2): 216–20. doi:10.1038/ng.275. PMC 2652837. PMID 19122664.
• Brautigam CA, Chuang JL, Tomchick DR, Machius M, Chuang DT (July 2005). "Crystal structure of human dihydrolipoamide dehydrogenase: NAD+/NADH binding and the structural basis of disease-causing mutations". Journal of Molecular Biology. 350 (3): 543–52. doi:10.1016/j.jmb.2005.05.014. PMID 15946682.
• Reed LJ, Hackert ML (June 1990). "Structure-function relationships in dihydrolipoamide acyltransferases". The Journal of Biological Chemistry. 265 (16): 8971–4. doi:10.1016/S0021-9258(19)38795-2. PMID 2188967.
• Ciszak EM, Makal A, Hong YS, Vettaikkorumakankauv AK, Korotchkina LG, Patel MS (January 2006). "How dihydrolipoamide dehydrogenase-binding protein binds dihydrolipoamide dehydrogenase in the human pyruvate dehydrogenase complex". The Journal of Biological Chemistry. 281 (1): 648–55. doi:10.1074/jbc.M507850200. PMID 16263718.
• Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, Kawaguchi T, et al. (December 2009). "A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population". Nature Genetics. 41 (12): 1325–9. doi:10.1038/ng.482. PMID 19915573. S2CID 20507558.
• Odièvre MH, Chretien D, Munnich A, Robinson BH, Dumoulin R, Masmoudi S, et al. (March 2005). "A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit gene (DLD) resulting in an atypical form of alpha-ketoglutarate dehydrogenase deficiency". Human Mutation. 25 (3): 323–4. doi:10.1002/humu.9319. PMID 15712224. S2CID 19929944.
• Brautigam CA, Wynn RM, Chuang JL, Machius M, Tomchick DR, Chuang DT (March 2006). "Structural insight into interactions between dihydrolipoamide dehydrogenase (E3) and E3 binding protein of human pyruvate dehydrogenase complex". Structure. 14 (3): 611–21. doi:10.1016/j.str.2006.01.001. PMC 2879633. PMID 16442803.
• Kim H (March 2006). "Activity of human dihydrolipoamide dehydrogenase is largely reduced by mutation at isoleucine-51 to alanine". Journal of Biochemistry and Molecular Biology. 39 (2): 223–7. doi:10.5483/bmbrep.2006.39.2.223. PMID 16584639.
• Sugden MC, Holness MJ (May 2003). "Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs". American Journal of Physiology. Endocrinology and Metabolism. 284 (5): E855-62. doi:10.1152/ajpendo.00526.2002. PMID 12676647.
• Wang YC, Wang ST, Li C, Chen LY, Liu WH, Chen PR, et al. (January 2008). "The role of amino acids T148 and R281 in human dihydrolipoamide dehydrogenase". Journal of Biomedical Science. 15 (1): 37–46. doi:10.1007/s11373-007-9208-9. PMID 17960497.
• Brown AM, Gordon D, Lee H, Caudy M, Hardy J, Haroutunian V, Blass JP (November 2004). "Association of the dihydrolipoamide dehydrogenase gene with Alzheimer's disease in an Ashkenazi Jewish population". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 131B (1): 60–6. doi:10.1002/ajmg.b.30008. PMID 15389771. S2CID 26098296.
• Wang YC, Wang ST, Li C, Liu WH, Chen PR, Chen LY, Liu TC (March 2007). "The role of N286 and D320 in the reaction mechanism of human dihydrolipoamide dehydrogenase (E3) center domain". Journal of Biomedical Science. 14 (2): 203–10. doi:10.1007/s11373-006-9136-0. PMID 17171578.
• Foster LJ, Rudich A, Talior I, Patel N, Huang X, Furtado LM, et al. (January 2006). "Insulin-dependent interactions of proteins with GLUT4 revealed through stable isotope labeling by amino acids in cell culture (SILAC)". Journal of Proteome Research. 5 (1): 64–75. doi:10.1021/pr0502626. PMID 16396496.
• Kim H (March 2005). "Asparagine-473 residue is important to the efficient function of human dihydrolipoamide dehydrogenase". Journal of Biochemistry and Molecular Biology. 38 (2): 248–52. doi:10.5483/bmbrep.2005.38.2.248. PMID 15826505.
• Hiromasa Y, Fujisawa T, Aso Y, Roche TE (February 2004). "Organization of the cores of the mammalian pyruvate dehydrogenase complex formed by E2 and E2 plus the E3-binding protein and their capacities to bind the E1 and E3 components". The Journal of Biological Chemistry. 279 (8): 6921–33. doi:10.1074/jbc.M308172200. PMID 14638692.
• Wynn RM, Kato M, Machius M, Chuang JL, Li J, Tomchick DR, Chuang DT (December 2004). "Molecular mechanism for regulation of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase complex by phosphorylation". Structure. 12 (12): 2185–96. doi:10.1016/j.str.2004.09.013. PMID 15576032.
• Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW, Dias-Neto E (April 2009). "Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation". BMC Psychiatry. 9: 17. doi:10.1186/1471-244X-9-17. PMC 2684104. PMID 19405953.

External links

• Dihydrolipoamide+dehydrogenase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.